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ABSTRACT 
 
Cervical cancer is one kind of many cancers that cause death to women around the world. Many 
studies had support the statement that inflammation has a strong linkage with cancer development. 
Several factors like proinflammatory factor can influence tumor cell microenvironment, and induce a 
faster proliferation. TNF-α is suspected can induce proliferation. While cancer itself can induce 
inflammation, which is marked by several marker. One of them is HMGB1, released from the cell as 
active secretory lysosomes or passive diffusion. Genistein has demonstrated growth inhibitory effects 
of various types of cancer cells. It inhibits tyrosine kinase pathway, which can be activated by TNF-α. 
One of those pathways that have the link with proliferation is p38. This study tries to reveal about 
inhibitory effect of genistein toward p38 pathway that had been activated by TNF-α. This research was 
conducted by exposing cultured HeLa cells with various doses of genistein for 90 minutes, and then 
exposed to TNF-α 10 ng / mL for 20 minutes. Observations were made with  a confocal microscope, by 
staining the cells with pp38-TRITC and HMGB1 antibody. The intensity was measured and analyzed by 
Fluoview software. The results suggest that there be significant differences between pp38 intranuclear 
intensity and HMGB1 extranuclear intensity of each dose of genistein (p = 0.000, ANOVA). pp38 and 
HMGB1 intensity were increased along with increasing genistein dose, but at high dose there were 
noted decreasing of pp38 and HMGB1 intensity. At apoptotic dose, pp38 and HMGB1 intensity were 
increased markedly, showing the effect of apoptosis. In general, increasing doses of genistein increase 
intranuclear p38 activation and HMGB1 extranuclear translocation. So there were a strong linkage 
between p38 activation and HMGB1 translocation in this study. 
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INTRODUCTION 
Cervical cancer is one kind of many cancers 
that cause death to women around the world [1]. 
Until now, cervical cancer is treated by operative, 
chemotherapy and radiotherapy, depend on its 
stadium [2]. Several studies had support the 
statement that inflammation has a strong linkage 
with cancer development. Many pathways are in-
volved, example like cyclooxygenase (COX-1 and 
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-2), free radicals, TGF-β and TNF-α [3]. Several 
factors like proinflammatory factor can influence 
tumor cells microenvironment, and induce a 
faster proliferation [4, 5]. TNF-α is suspected can 
induce proliferation through NF-ĸB pathway [3]. 
In his review, Rakoff-Nahoum also writes cancer 
also induce inflammation, which marked by 
HMGB1 release. HMGB1 is an intranuclear 
protein, together histone they folded  DNA and a 
parted when the DNA transcription process 
happen. It is a mobile molecule and can migrate 
from the nucleus to the cytoplasm through the 
nuclear pore [6]. It serves as a cytokine when 
released in the extracellular environment by 
inflamed and necrotic cells [7]. After translated, 
HMGB1 undergone various modifications to be 
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able to function. One important modification that 
occurs on HMGB1 is acetylation, which causes 
HMGB1 out of the cell nucleus and can not return 
to the nucleus [8]. Acetylated HMGB1 will come 
out actively as secretory lysosomes [9]. Outside the 
cell, it bounded firmly to  the RAGE receptor 
which is a potent mediator for inflammation [10]. 
HMGB1 overexpression inhibits apoptosis, which 
supports the argument that these molecules may 
act as antiapoptotic oncoprotein, and HMGB1 
expression found increase in several different 
tumor types [11]. Thus, allegedly HMGB1 
translocation from nucleus into the cytoplasm of 
the cancer cells can affect defense toward 
apoptosis. A model of the nature of cancer cells is 
HeLa cells culture. HeLa cell is a cell culture 
derived from a tissue biopsy of the cervix uteri 
Henrietta Lacks, a cervical cancer patients which 
taken in 1951 [12]. HeLa cells that induced by 
TNF-α can provide an illustration of the role of 
chronic inflammation in cancer. In a previous 
study, it was found that the induction of TNF-α in 
HeLa cell cultures can increase HMGB1 
translocation from the nucleus to the cytoplasm, 
which may imply that the inflammatory pathway in 
this cell culture has been activated. From this 
preliminary research, allegedly that the pathways 
involved in the induction of HMGB1 translocation 
from the nucleus to the cytoplasm is the MAPK 
pathway. One group of protein kinases that are 
activated by inflammatory cytokines is p38. TNF 
and IL-1 activates p38 iso-forms to encourage the 
deployment of TRAF adapter proteins to the 
intracellular domain of the receptor origin. TRAF 
deployment activate various of MAPKKK 
involved in the activation of p38 [13]. Thus, it can 
be presumed that the induction of TNF - α 
activates the p38 pathway that encourages the 
release of HMGB1. The release of the intranuclear 
molecules will exacerbate the inflammatory process 
and promote the occurrence of metastasis. 
Genistein which is the major isoflavones found in 
soybeans, has demonstrated growth inhibitory 
effects of various types of cancer cells in vitro and 
vivo without toxicity to normal tissues [14]. It 
inhibits protein-tyrosine kinase and topoisomerase-
II activity (DNA topoisomerase, type II), and is 
used as an antineoplastic and antitumor agent. 
Genistein can modify histone H3 with acetylate the 
histone proteins [15]. This study is trying to 
uncover the potential of genistein as the new hope 
of the cancer management, especially cervical 
cancer. In this study, genistein can inhibit the 
translocation of HMGB1 allegedly from the 
nucleus to the cytoplasm, which is activated by the 
p38 pathway in cultured HeLa cells induced by 
TNF - α. Thus, further research on the potential of 
genistein can be done. 
 
MATERIALS AND METHODS 
 
Cell Lines 
Hela cells were obtained from ATCC. HeLa 
cells were cultured in Modified Eagle's medium 
(MEM) supplemented with 10% fetal bovine 
serum (Sigma), 100 IU/mL of penicillin and 
1.25% penicillin-streptomycin, in 5% CO2 
humidified atmosphere. The cells(105) were 
plated on coverslips in 15,6 mm diameter 24-well 
plate (Corning Costar, US). Cells were observed 
48 h until confluent. When the cells have been 
confluent, Hela cells were given various dose of 
Genistein for 90 minutes [16]. After that, the 
cells activated with 10 ng/ml [17] TNF-
α(#570102; R&D system, Minneapolis, US) for 
20 minutes [18]. 
 
Immunofluoresence  
The cells were fixed in situ by para-
formaldehyde 4% (Sigma-Aldrich; Buchs, 
Switzerland) for 15 minutes, washed three times 
with PBS for five minutes, and then for five 
minutes with PBS containing 0.1% BSA (Sigma-
Aldrich; Buchs, Switzerland). For the detection 
of HMGB1 and pp38, the cells were incubated 
with the HMGB1 IgG mouse monoclonal 
antibody (#MAB1690; R&D system, 
Minneapolis, US)diluted in 20 µg/mL in PBS-
BSA for 45 min at room temperature (RT) in a 
humid atmosphere. This specificity has been 
proved by others [19]. To remove unbound 
primary antibodies, cells were washed three times 
for 5 minutes with PBS; subsequently, the 
secondary antibody,  FITC secondary 
antibody(#F7250; Sigma-Aldrich, Buchs, 
Switzerland) were diluted in 1:2500 in PBS-BSA, 
was applied for 45 min at RT and unbound 
antibodies were removed as described above. For 
nuclear contrast, propidium iodide (#81845; 
Sigma-Aldrich, Missouri, US) were used in 1 
mg/mL and applied for 5 minutes. In another 
plate, the cells were incubated with the pp38-
TRITC conjugated IgM mouse mono-clonal 
antibodyfrom (#sc-7973 TRITC, Santa Cruz; 
Texas, US) diluted in 1:100 in PBS-BSA for 45 
minutes. Unbound antibodies were removed, and 
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cells dissolved in PBS were immediately studied 
with the confocal microscope.  
 
Confocal Imaging 
Confocal fluorescent image were obtained by 
Olympus LV1000 confocal microscope scan head 
with 400x objective. Sequential excitation at 488 
nm for FITC, 568 nm for propidium iodide and 
TRITC, and was provided by argon gas lasers, 
respectively. Emission filter 40x/1.30 Oil UPlan 
FLN were used for collecting green dye and 
60x/1.35 Oil Uplansapowere used for collecting 
red dye. For thedetection of pp38, TRITC was 
used in channel one. For thedetection of 
HMGB1, FITC was used in channel one and PI 
were used in channel two. After sequential 
excitation, green and red fluorescent of the cells 
was saved and analyzed by Fluoview 1.7a version 
software. 
 
RESULTS AND DISCUSSION 
 
Intensity of intracellular phospho-p38  
One of the possible causes of HMGB1 
translocate from the cytosol to the intranuclearis 
caused by activation of p38 MAPK cascade. 
Activated p38 can be detected with antibody-
phosphorylated p38 (pp38) which had been 
bound with fluorescent Rhodamine, and 
observed with a confocal microscope Olympus. 
Analysis result of thetest using One-Way 
ANOVA on the intensity of intracellular pp38 
shows the results of homogeneity of variance 
with significant variance (p = 0:02). Results of 
One Way ANOVA showed average difference 
intensity pp38 significant (p = 0.000) between 
cell culture negative control, positive control and 
treatment.  
Post Hoc Tukey HSD study showed that p38 
activity is significantly increased at dose 10 nM, 
100 nM, and 50 µM compared to the negative 
control (P <0.05). Meanwhile, when compared 
with the positive control, p38 activity was not 
increased significantly in all treatment doses. At 
dose 1 nM and 10 µM found decreased activity, 
though not statistically significant when 
compared with the positive control (Figure 1A 
and 1B). p38 activity significantly increased at a 
dose 10 nM, 100 nM and 50 µM compared to the 
negative control ( P <0.05 ). Meanwhile, when 
compared with the positive control, p38 activity 
was not significantly increased in all treatment 
doses. At a dose of 1 nM and 10 µM found 
decreased activity, though not statistically 
significant when compared with the positive 
control. Other studies have suggested that 
genistein inhibits the growth of HeLa cells, but 
increased the phosphorylation of p38 [20]. 
From several previous studies, opposing 
effect have found. Huang said that genistein 50 
µM can inhibit the activation of p38 when given 
before exposure to TGF - β [21]. Lakhsman 
support the statement, that genistein intake of 
250 mg / kg in mice, resulted in plasma genistein 
concentration of 1.3 µM, can increase the 
expression of p38 but lowered it activation [22]. 
Both studies was conducted on cancer cells 
culture which are sensitive to estrogen receptors, 
namely PC3, PC3-M and prostate cancer cell 
cultures. It means that the effects of estrogen 
receptors on both study are still not taken into 
account. Another study mentioned that the 
genistein at dose 45 µM can increase the activity 
of p38 from the 15th minute until 120th [16]. 
Several studies support statement that p38 can 
activate estrogen receptors in endometrial cells 
[23, 24]. 
In cell culture with strong expression of 
estrogen receptors, genistein tends to act as 
estrogen agonists at low concentrations ( <5 
µM), and became estrogen antagonist at high 
concentrations (> 10 µM) [25]. At nanomolar 
concentrations, the effects of tyrosine kinase 
inhibition are difficult to achieve because it is too 
low [26]. Genistein itself has more potent 
selectivity toward estrogen receptor-β than 
estrogen receptor-α [26, 27]. While in cervix 
cancer cells, estrogen receptor type that more 
dominant is estrogen receptor-α. Decreased 
levels of estrogen receptor-α in cervical cancer 
cells can increase malignancy of cancer cells [28, 
29, 30]. Thus, it can be presumed that there are 
other pathways exist in addition to the estrogen 
receptor-α and -β that can increase the activation 
of p38 in our study. 
Xie et al. 2013 using the genistein as an 
apoptosis inducer agent at a dose 15 mg/mL [31]. 
This made clear by other studies stating that p38 
is one of the apoptosis cell intermediate [32, 33]. 
It  explains increasing in the intensity of p38 at 
dose 50 µM, where this dose as indicated on 
Szliszka, et al., 2008 is apoptotic dose of 
genistein [34]. The results of the studies 
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mentioned above, it can be concluded that 
genistein has different effects on different cell 
cultures, with different doses. The phenomenon 
can be affected by the estrogenic effects of 
genistein; receptor tendencies or genistein doses 
that given. Thus, it may explain the results of our 
study, which low doses exposure of genistein (1-
100 nM) increases the effect of p38 activation, 
whereas at higher doses (1-10 µM or more) are 
inhibitors for p38. At apoptotic dose, p38 
increased again due to the activation of apoptotic 
pathways. 
 
 
Figure1.  A. Comparison of the mean intensity of intracellular pp38 in cultured HeLa cells without treatment (negative 
control) exposed to TNF-α treatment of 10 ng (positive control), and with various concentrations of genistein 
exposure (treatment). Note : K– (negative control), K+ (positive control), 1N (1 nM genistein), 10N (10 nM 
genistein), 100N (100 nM genistein), 1M (1 µM genistein), 10M (10 µM genistein), dan 50M (50 µM genistein). B. 
P38 antibody-TRITC staining and confocal microscopy observations. HeLa cell cultures were exposed to various 
concentrations of genistein for 90 minutes and exposed to TNF-α 10 ng / ml for 20 minutes. 
 
 
 
 
Figure 3. A. Comparison of the mean intensity of extranuclear HMGB1 in cultured HeLa cells without treatment (negative 
control), exposed to TNF-α treatment of 10 ng (positive control), and with various concentrations of genistein 
exposure (treatment). Note : K– (negative control), K+ (positive control), 1N (1 nM genistein), 10N (10 nM 
genistein), 100N (100 nM genistein), 1M (1 µM genistein), 10M (10 µM genistein), dan 50M (50 µM genistein). B. 
HMGB1/FITC staining and confocal microscopy observations. HeLa cell cultures were exposed to various 
concentrations of genistein for 90 minutes and exposed to TNF-α 10 ng / ml for 20 minutes. 
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Figure 5. Pearson test results obtained that the relationship 
between variables is significant and substantial. 
 
Intensity of HMGB1 extranuclear  
HMGB1 which stained with primary antibodies 
and fluorescent FITC is coming out from 
intranuclear. HMGB1 fluorescence intensity was 
measured using a confocal microscope Olympus. 
Analysis of test results using One-Way ANOVA 
on the intensity of HMGB1 extra-nuclear shows 
the results of homogeneity of variance with the 
variance was not significant (p = 0.52). Results of 
One Way ANOVA showed average difference 
intensity of HMGB1 were significantly (p = 0.000) 
between cell culture negative control, positive 
control and treatment.  
The Post Hoc Tukey HSD analysis showed that 
HMGB1 significantly increased the number in the 
cytosol at dose 1 nM, 100 nM and 50 µM 
compared to the negative control (P <0.05). 
Meanwhile, when compared with the positive 
control, HMGB1 did not significantly increase in 
the cytosol in all treatment doses, except 50 µM (P 
<0.05). At dose 1 µM and 10 µM found decreased 
intensity, though not statistically significant. 
However compared to dose 100 nM, both dose can 
significantly reduce the intensity of HMGB1 in the 
cytosol (P <0.05) (Figure 3A and 3B).  
 The Post Hoc Tukey HSD analysis showed 
that HMGB1 significantly increased the amount in 
the cytosol in a dose of 1 nM, 100 nM and 50 µM 
when compared to the negative control (P <0.05). 
Meanwhile, when compared to the positive 
control, HMGB1 did not increase the amount in 
the cytosol significantly in all treatment doses, 
except 50 µM (P <0.05). At dose 1 µM and 10 µM 
found decreased activity, though not significant 
statistically. However toward dose 100 nM, both 
treatments can significantly reduce the intensity of 
HMGB1 in the cytosol (p <0.05). That is, in 
general, increasing doses of genistein also increase 
the amount of HMGB1 that translocated into the 
cytosol. 
Induction of TNF-α can activate p38 pathway 
[14, 35], which finally activates MSK1 [36]. MSK1 
activation would lead to activation of CREB 
(cAMP Response Element Binding Protein) [37]. 
This is confirmed by research Gustin (2004) [38], 
in which TNF-α can activate CREB through p38-
MSK1 pathway via TNFR-1 receptor [38]. 
Activation of phosphorylated CREB binds to 
CREB-binding protein (CBP). After CBP 
activated, it will bind to p300 both with Histone 
Acetyltransferase activity [39]. Substrates of 
CBP/p300 is not only histones, but also non-
histone proteins other [40], including HMGB1 [8]. 
Acetylated HMGB1 will be separated from DNA 
binding [8] because its domain of DNA on 
HMGB1 Nuclear Localization Sequence (NLS) 
experienced acetylation [39]. In addition, acetylated 
HMGB1 also will undergo translocation through 
CRM1 or exportin [41] and can not survive much 
longer in the nucleus [8]. This is consistent with 
the findings in our study where HMGB1 
translocation to nucleus increased along with p38 
activation. In conclusion, increasing doses of 
genistein increase intranuclear p38 activation and 
HMGB1 extra-nuclear translocation. Moreover, 
there were a strong linkage between p38 activation 
and HMGB1 translocation in this study.  
Pearson test results obtained that the 
relationship between variables is significant, with p 
= 0.000, which means a significant relationship 
between the increase in the intensity of pp38 with 
an increase in the intensity of HMGB1. R = 0773 
show an association with high strength. Positive 
value (+) means that between pp38 and HMGB1 
has a unidirectional relationship, the higher the 
intensity of pp38, the higher the intensity of 
HMGB1 (Figure 5). 
 
CONCLUSIONS  
 
From the experiment, it can be concluded that 
exposure various doses of genistein increase 
intranuclear p38 activation and HMGB1 
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extranuclear translocations in a biphasic pattern. 
Genistein effects increase p38 phosphorylation and 
HMGB1 translocation in nanomolar doses, but 
decreased in micromolar doses. But overall, 
genistein increase p38 activation and HMGB1 
acetylation. So there were a probable linkage 
between p38 activation and HMGB1 translocation 
in this study. 
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